MedPath

Desitin Arzneimittel Gmbh

Desitin Arzneimittel Gmbh logo
🇳🇴Norway
Ownership
Private
Established
1919-01-01
Employees
251
Market Cap
-
Website
http://www.desitin.de

Clinical Trials

20

Active:8
Completed:11

Trial Phases

3 Phases

Phase 1:10
Phase 2:1
Phase 3:2

Drug Approvals

4

CIMA_AEMPS:4

Drug Approvals

ZEDEPTINE 12 MG/ML SOLUCION ORAL EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

OSPOLOT 20 MG/ML SUSPENSIÓN ORAL

Approval Date
Jul 14, 2025
CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (76.9%)
Phase 3
2 (15.4%)
Phase 2
1 (7.7%)

Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets

Phase 1
Completed
Conditions
Multiple Drug Use
Interventions
Drug: Sodium valproate 500 MG
Drug: Valproic Acid 500 MG
First Posted Date
2024-01-19
Last Posted Date
2024-01-23
Lead Sponsor
Desitin Arzneimittel GmbH
Target Recruit Count
22
Registration Number
NCT06214130
Locations
🇨🇦

Biopharma Services INC, Toronto, Canada

Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.

Phase 1
Completed
Conditions
Food-drug Interaction
Interventions
First Posted Date
2024-01-18
Last Posted Date
2024-01-22
Lead Sponsor
Desitin Arzneimittel GmbH
Target Recruit Count
28
Registration Number
NCT06211283
Locations
🇨🇦

Biopharma Services INC, Toronto, Canada

Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

Phase 1
Completed
Conditions
Fasting
Interventions
First Posted Date
2024-01-10
Last Posted Date
2024-01-10
Lead Sponsor
Desitin Arzneimittel GmbH
Target Recruit Count
24
Registration Number
NCT06199791
Locations
🇨🇦

Biopharma Services INC, Toronto, Canada

Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA)

Phase 2
Completed
Conditions
Obstructive Sleep Apnea
Interventions
First Posted Date
2022-02-11
Last Posted Date
2023-11-29
Lead Sponsor
Desitin Arzneimittel GmbH
Target Recruit Count
298
Registration Number
NCT05236842
Locations
🇧🇪

Pneumocare SRL, Namur, Belgium

Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration

Phase 1
Completed
Conditions
Fasted State
Interventions
First Posted Date
2014-04-17
Last Posted Date
2014-04-17
Lead Sponsor
Desitin Arzneimittel GmbH
Target Recruit Count
12
Registration Number
NCT02116465
Locations
🇧🇬

Department of Clinical Pharmacology, Sofia, Bulgaria

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.